載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.2361
−US$0.0101 · -4.10%
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
前收盤價
US$0.2361
−US$0.0101 · -4.10%
盤中時間採用ET。市場資料可能有所延遲。
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
日內區間
目前US$0.2361
52週區間
目前US$0.2361
盤中時間採用ET。市場資料可能有所延遲。
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
日內區間
目前US$0.2361
52週區間
目前US$0.2361
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 126.9萬 USD | 48.6萬 USD | 106.4萬 USD | −22.7萬 USD | 110.89萬 USD |
| 毛利 | 126.9萬 USD | 48.6萬 USD | 106.4萬 USD | −22.7萬 USD | 110.89萬 USD |
| 研究與開發 | 5497.4萬 USD | 3937.5萬 USD | 2002.2萬 USD | 4437.7萬 USD | 3540.78萬 USD |
| 銷售、一般及管理費用 | 1842.1萬 USD | 1708.4萬 USD | 1406.3萬 USD | 1466.4萬 USD | 1324.8萬 USD |
| 營業費用 | 7339.5萬 USD | 5645.9萬 USD | 3408.5萬 USD | 5904.1萬 USD | 4888.78萬 USD |
| 利息收入 | 244.1萬 USD | 455.7萬 USD | 335.1萬 USD | 4.9萬 USD | 2萬 USD |
| 利息支出 | — | — | — | 2.3萬 USD | — |
| 折舊和攤銷 | 73.3萬 USD | 63.5萬 USD | 56.8萬 USD | 53.2萬 USD | 71.11萬 USD |
| 營業利益 | −7212.6萬 USD | −5597.3萬 USD | −3302.1萬 USD | −5926.8萬 USD | −4777.89萬 USD |
| 淨利 | −6968.5萬 USD | −5141.8萬 USD | −2936.2萬 USD | −5924.8萬 USD | −4776.24萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$0.95
上漲空間 302.37%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年6月7日 | 1:30 | — | — |
股票分割 | 2014年8月14日 | 1:20 | — | — |
已生效 2023年6月7日
1:30
已生效 2014年8月14日
1:20
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
